{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T02:38:22Z","timestamp":1788230302985,"version":"build-2803163510"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T00:00:00Z","timestamp":1568678400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T00:00:00Z","timestamp":1568678400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1038\/s41375-019-0573-y","type":"journal-article","created":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T13:05:09Z","timestamp":1568725509000},"page":"543-552","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHL"],"prefix":"10.1038","volume":"34","author":[{"name":"the Emed Demonstrator Project","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5896-3200","authenticated-orcid":false,"given":"Annette M.","family":"Staiger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"German High Grade Non-Hodgkin\u2019s Lymphoma Study Group (DSHNHL)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Altenbuchinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marita","family":"Ziepert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Kohler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Horn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Huttner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin S.","family":"H\u00fcttl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunther","family":"Glehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7208-4117","authenticated-orcid":false,"given":"Wolfram","family":"Klapper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Szczepanowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9543-4084","authenticated-orcid":false,"given":"Julia","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred C.","family":"Feller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"M\u00f6ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin-Leo","family":"Hansmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viola","family":"Poeschel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Held","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Loeffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Schmitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenz","family":"Tr\u00fcmper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Pukrop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Rosenwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"German","family":"Ott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Spang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,17]]},"reference":[{"key":"573_CR1","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. International Agency for Research on Cancer: Lyon; 2017."},{"key":"573_CR2","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"AA Alizadeh","year":"2000","unstructured":"Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503\u201311.","journal-title":"Nature"},{"key":"573_CR3","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1056\/NEJMoa012914","volume":"346","author":"A Rosenwald","year":"2002","unstructured":"Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937\u201347.","journal-title":"N Engl J Med"},{"key":"573_CR4","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.cell.2017.09.027","volume":"171","author":"A Reddy","year":"2017","unstructured":"Reddy A, Zhang J, Davis NS, Moffitt AB, Love CL, Waldrop A, et al. Genetic and functional drivers of diffuse large B cell lymphoma. Cell. 2017;171:481\u201394. e15","journal-title":"Cell"},{"key":"573_CR5","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","volume":"378","author":"R Schmitz","year":"2018","unstructured":"Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. New Engl J Med. 2018;378:1396\u2013407.","journal-title":"New Engl J Med"},{"key":"573_CR6","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","volume":"30","author":"NA Johnson","year":"2012","unstructured":"Johnson NA, Slack GW, Savage KJ, Connors JM, Ben-Neriah S, Rogic S, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30:3452\u20139.","journal-title":"J Clin Oncol"},{"key":"573_CR7","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1182\/blood-2012-06-435842","volume":"121","author":"H Horn","year":"2013","unstructured":"Horn H, Ziepert M, Becher C, Barth TFE, Bernd H-W, Feller AC, et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood. 2013;121:2253\u201363.","journal-title":"Blood"},{"key":"573_CR8","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1038\/leu.2008.230","volume":"22","author":"W Klapper","year":"2008","unstructured":"Klapper W, Stoecklein H, Zeynalova S, Ott G, Kosari F, Rosenwald A, et al. Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Leukemia. 2008;22:2226\u20139.","journal-title":"Leukemia"},{"key":"573_CR9","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1182\/blood-2011-03-345272","volume":"118","author":"AA Alizadeh","year":"2011","unstructured":"Alizadeh AA, Gentles AJ, Alencar AJ, Liu CL, Kohrt HE, Houot R, et al. Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment. Blood. 2011;118:1350\u20138.","journal-title":"Blood"},{"key":"573_CR10","doi-asserted-by":"publisher","first-page":"4836","DOI":"10.1182\/blood-2010-12-322362","volume":"117","author":"G Gutierrez-Garcia","year":"2011","unstructured":"Gutierrez-Garcia G, Cardesa-Salzmann T, Climent F, Gonzalez-Barca E, Mercadal S, Mate JL, et al. Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Blood. 2011;117:4836\u201343.","journal-title":"Blood"},{"key":"573_CR11","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/ajh.23398","volume":"88","author":"C Keane","year":"2013","unstructured":"Keane C, Gill D, Vari F, Cross D, Griffiths L, Gandhi M. CD4(+) tumor infiltrating lymphocytes are prognostic and independent of R-IPI in patients with DLBCL receiving R-CHOP chemo-immunotherapy. Am J Hematol. 2013;88:273\u20136.","journal-title":"Am J Hematol"},{"key":"573_CR12","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","volume":"359","author":"G Lenz","year":"2008","unstructured":"Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359:2313\u201323.","journal-title":"N Engl J Med."},{"key":"573_CR13","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1309\/AJCPJX4BJV9NLQHY","volume":"135","author":"PN Meyer","year":"2011","unstructured":"Meyer PN, Fu K, Greiner T, Smith L, Delabie J, Gascoyne R, et al. The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab. Am J Clin Pathol. 2011;135:54\u201361.","journal-title":"Am J Clin Pathol"},{"key":"573_CR14","doi-asserted-by":"publisher","first-page":"151","DOI":"10.20892\/j.issn.2095-3941.2017.0007","volume":"14","author":"AG Abdou","year":"2017","unstructured":"Abdou AG, Asaad N, Kandil M, Shabaan M, Shams A. Significance of stromal-1 and stromal-2 signatures and biologic prognostic model in diffuse large B-cell lymphoma. Cancer Biol Med. 2017;14:151\u201361.","journal-title":"Cancer Biol Med"},{"key":"573_CR15","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1200\/JCO.2012.43.4589","volume":"31","author":"DW Scott","year":"2013","unstructured":"Scott DW, Chan FC, Hong F, Rogic S, Tan KL, Meissner B, et al. Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma. J Clin Oncol. 2013;31:692\u2013700.","journal-title":"J Clin Oncol"},{"key":"573_CR16","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1182\/blood-2013-11-536433","volume":"123","author":"DW Scott","year":"2014","unstructured":"Scott DW, Wright GW, Williams PM, Lih C-J, Walsh W, Jaffe ES, et al. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood. 2014;123:1214\u20137.","journal-title":"Blood"},{"key":"573_CR17","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1200\/JCO.2016.70.7901","volume":"35","author":"DW Scott","year":"2017","unstructured":"Scott DW, Abrisqueta P, Wright GW, Slack GW, Mottok A, Villa D, et al. New molecular assay for the proliferation signature in mantle cell lymphoma applicable to formalin-fixed paraffin-embedded biopsies. J Clin Oncol. 2017;35:1668\u201377.","journal-title":"J Clin Oncol"},{"key":"573_CR18","doi-asserted-by":"publisher","first-page":"2848","DOI":"10.1200\/JCO.2014.60.2383","volume":"33","author":"DW Scott","year":"2015","unstructured":"Scott DW, Mottok A, Ennishi D, Wright GW, Farinha P, Ben-Neriah S, et al. Prognostic significance of diffuse large B-cell lymphoma cell of origin determined by digital gene expression in formalin-fixed paraffin-embedded tissue biopsies. J Clin Oncol. 2015;33:2848\u201356.","journal-title":"J Clin Oncol"},{"key":"573_CR19","doi-asserted-by":"crossref","unstructured":"Clot G, Jares P, Gin\u00e9 E, Navarro A, Royo C, Pinyol M, et al. A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome. Blood. 2018;132:413\u201322.","DOI":"10.1182\/blood-2018-03-838136"},{"key":"573_CR20","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","volume":"9","author":"M Pfreundschuh","year":"2008","unstructured":"Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9:105\u201316.","journal-title":"Lancet Oncol"},{"key":"573_CR21","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1200\/JCO.2013.51.4505","volume":"32","author":"G Held","year":"2014","unstructured":"Held G, Murawski N, Ziepert M, Fleckenstein J, P\u00f6schel V, Zwick C, et al. Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma. J Clin Oncol. 2014;32:1112\u20138.","journal-title":"J Clin Oncol"},{"key":"573_CR22","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1093\/annonc\/mdu208","volume":"25","author":"N Murawski","year":"2014","unstructured":"Murawski N, Pfreundschuh M, Zeynalova S, Poeschel V, H\u00e4nel M, Held G, et al. Optimization of rituximab for the treatment of DLBCL (I): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL. Ann Oncol 2014;25:1800\u20136.","journal-title":"Ann Oncol"},{"key":"573_CR23","doi-asserted-by":"publisher","first-page":"4127","DOI":"10.1200\/JCO.2013.54.6861","volume":"32","author":"M Pfreundschuh","year":"2014","unstructured":"Pfreundschuh M, Poeschel V, Zeynalova S, H\u00e4nel M, Held G, Schmitz N, et al. Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group. J Clin Oncol. 2014;32:4127\u201333.","journal-title":"J Clin Oncol"},{"key":"573_CR24","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/S1470-2045(11)70235-2","volume":"12","author":"M Pfreundschuh","year":"2011","unstructured":"Pfreundschuh M, Kuhnt E, Tr\u00fcmper L, Osterborg A, Trneny M, Shepherd L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011;12:1013\u201322.","journal-title":"Lancet Oncol"},{"key":"573_CR25","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/S1470-2045(12)70481-3","volume":"13","author":"N Schmitz","year":"2012","unstructured":"Schmitz N, Nickelsen M, Ziepert M, Haenel M, Borchmann P, Schmidt C, et al. Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). Lancet Oncol. 2012;13:1250\u20139.","journal-title":"Lancet Oncol"},{"key":"573_CR26","doi-asserted-by":"crossref","unstructured":"Friedrichs B, Nickelsen M, Ziepert M, Altmann B, Haenel M, Viardot A, et al. Doubling rituximab in high-risk patients with aggressive B-cell lymphoma -results of the DENSE-R-MegaCHOEP trial. Br J Haematol. 2019;184:760\u20138.","DOI":"10.1111\/bjh.15710"},{"key":"573_CR27","volume-title":"WHO classification of tumours of haematopoetic and lymphoid tissues.","year":"2008","unstructured":"Swerdlow SH, Campo E, Jaffe ES, Harris NL, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoetic and lymphoid tissues. Lyon, France: IARC Press; 2008."},{"key":"573_CR28","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/bjh.14812","volume":"179","author":"M Szczepanowski","year":"2017","unstructured":"Szczepanowski M, Lange J, Kohler CW, Masque-Soler N, Zimmermann M, Aukema SM, et al. Cell-of-origin classification by gene expression and MYC-rearrangements in diffuse large B-cell lymphoma of children and adolescents. Br J Haematol. 2017;179:116\u20139.","journal-title":"Br J Haematol"},{"key":"573_CR29","doi-asserted-by":"publisher","first-page":"996","DOI":"10.3324\/haematol.2010.037408","volume":"96","author":"TM Cardesa-Salzmann","year":"2011","unstructured":"Cardesa-Salzmann TM, Colomo L, Gutierrez G, Chan WC, Weisenburger D, Climent F, et al. High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy. Haematologica. 2011;96:996\u20131001.","journal-title":"Haematologica"},{"key":"573_CR30","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1182\/blood-2013-06-508937","volume":"122","author":"N Masque-Soler","year":"2013","unstructured":"Masque-Soler N, Szczepanowski M, Kohler CW, Spang R, Klapper W. Molecular classification of mature aggressive B-cell lymphoma using digital multiplexed gene expression on formalin-fixed paraffin-embedded biopsy specimens. Blood. 2013;122:1985\u20136.","journal-title":"Blood"},{"key":"573_CR31","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1182\/blood-2008-01-136465","volume":"112","author":"W Klapper","year":"2008","unstructured":"Klapper W, Szczepanowski M, Burkhardt B, Berger H, Rosolowski M, Bentink S, et al. Molecular profiling of pediatric mature B-cell lymphoma treated in population-based prospective clinical trials. Blood. 2008;112:1374\u201381.","journal-title":"Blood"},{"key":"573_CR32","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1093\/biostatistics\/4.2.249","volume":"4","author":"RA Irizarry","year":"2003","unstructured":"Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics (Oxf, Engl). 2003;4:249\u201364.","journal-title":"Biostatistics (Oxf, Engl)"},{"key":"573_CR33","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1093\/bioinformatics\/btg405","volume":"20","author":"L Gautier","year":"2004","unstructured":"Gautier L, Cope L, Bolstad BM, Irizarry RA. affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics. 2004;20:307\u201315.","journal-title":"Bioinformatics"},{"key":"573_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v033.i01","volume":"33","author":"J Friedman","year":"2010","unstructured":"Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw. 2010;33:1\u201322.","journal-title":"J Stat Softw"},{"key":"573_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v039.i05","volume":"39","author":"N Simon","year":"2011","unstructured":"Simon N, Friedman J, Hastie T, Tibshirani R. Regularization paths for Cox's proportional hazards model via coordinate descent. J Stat Softw. 2011;39:1\u201313.","journal-title":"J Stat Softw"},{"key":"573_CR36","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1093\/bioinformatics\/btx488","volume":"33","author":"M Altenbuchinger","year":"2017","unstructured":"Altenbuchinger M, Schwarzfischer P, Rehberg T, Reinders J, Kohler CW, Gronwald W, et al. Molecular signatures that can be transferred across different omics platforms. Bioinforma. 2017;33:2790.","journal-title":"Bioinforma"},{"key":"573_CR37","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1038\/leu.2015.43","volume":"29","author":"H Horn","year":"2015","unstructured":"Horn H, Ziepert M, Wartenberg M, Staiger AM, Barth TFE, Bernd H-W, et al. Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma. Leukemia. 2015;29:1564\u201370.","journal-title":"Leukemia"},{"key":"573_CR38","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1200\/JCO.2016.70.3660","volume":"35","author":"AM Staiger","year":"2017","unstructured":"Staiger AM, Ziepert M, Horn H, Scott DW, Barth TFE, Bernd H-W, et al. Clinical impact of the cell-of-origin classification and the MYC\/BCL2 dual expresser status in diffuse large B-cell lymphoma treated within prospective clinical trials of the german high-grade non-hodgkin's lymphoma study group. J Clin Oncol. 2017;35:2515\u201326.","journal-title":"J Clin Oncol"},{"key":"573_CR39","doi-asserted-by":"publisher","first-page":"4916","DOI":"10.1182\/blood-2010-03-276766","volume":"116","author":"G Ott","year":"2010","unstructured":"Ott G, Ziepert M, Klapper W, Horn H, Szczepanowski M, Bernd H-W, et al. Immunoblastic morphology but not the immunohistochemical GCB\/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. Blood. 2010;116:4916\u201325.","journal-title":"Blood"},{"key":"573_CR40","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nrc3774","volume":"14","author":"DW Scott","year":"2014","unstructured":"Scott DW, Gascoyne RD. The tumour microenvironment in B cell lymphomas. Nat Rev Cancer. 2014;14:517\u201334.","journal-title":"Nat Rev Cancer"},{"key":"573_CR41","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1200\/JCO.2010.33.4623","volume":"29","author":"J Brody","year":"2011","unstructured":"Brody J, Kohrt H, Marabelle A, Levy R. Active and passive immunotherapy for lymphoma: proving principles and improving results. J Clin Oncol. 2011;29:1864\u201375.","journal-title":"J Clin Oncol"},{"key":"573_CR42","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3324\/haematol.2014.113472","volume":"100","author":"S Riihij\u00e4rvi","year":"2015","unstructured":"Riihij\u00e4rvi S, Fiskvik I, Taskinen M, Vajavaara H, Tikkala M, Yri O, et al. Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial. Haematologica. 2015;100:238\u201345.","journal-title":"Haematologica"},{"key":"573_CR43","first-page":"701","volume":"39","author":"WM Huang","year":"2018","unstructured":"Huang WM, Wei YQ, Feng R. The multi-roles of tumor associated macrophages in diffuse large B cell lymphoma. Zhonghua Xue Ye Xue Za Zhi. 2018;39:701\u20134.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"573_CR44","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/hon.2142","volume":"33","author":"F Marchesi","year":"2015","unstructured":"Marchesi F, Cirillo M, Bianchi A, Gately M, Olimpieri OM, Cerchiara E, et al. High density of CD68+\/CD163+ tumour-associated macrophages (M2-TAM) at diagnosis is significantly correlated to unfavorable prognostic factors and to poor clinical outcomes in patients with diffuse large B-cell lymphoma. Hematol Oncol 2015;33:110\u20132.","journal-title":"Hematol Oncol"},{"key":"573_CR45","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1007\/s12032-011-0123-6","volume":"29","author":"LiaoH Cai Q-c","year":"2012","unstructured":"Cai Q-c LiaoH, Lin S-x, Xia Y, Wang X-x, Gao Y, et al. High expression of tumor-infiltrating macrophages correlates with poor prognosis in patients with diffuse large B-cell lymphoma. Med Oncol. 2012;29:2317\u201322.","journal-title":"Med Oncol"},{"key":"573_CR46","unstructured":"Ciavarella S, Vegliante MC, Fabbri M, Summa S de, Melle F, Motta G, et al. Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue. Ann. Oncol. 2018;29:2363\u201370."},{"key":"573_CR47","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1093\/bioinformatics\/btw598","volume":"33","author":"M Altenbuchinger","year":"2017","unstructured":"Altenbuchinger M, Rehberg T, Zacharias HU, St\u00e4mmler F, Dettmer K, Weber D, et al. Reference point insensitive molecular data analysis. Bioinforma. 2017;33:219\u201326.","journal-title":"Bioinforma"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41375-019-0573-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-019-0573-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-019-0573-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:38:08Z","timestamp":1684618688000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-019-0573-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,17]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["573"],"URL":"https:\/\/doi.org\/10.1038\/s41375-019-0573-y","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,17]]},"assertion":[{"value":"4 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}